TABLE 2.
Literature review of all clinical cases to date
| Author | Age (years) | Sex | Method of diagnosis and/or type of tissue sampled | ALK detection | Stage | Smoking history (pack‐year) | Prior treatment | ALK inhibitor | Efficacy | Duration of treatment (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Kimh et al. 2013 10 | 36 | F | Bronchial biopsy of the cervical lymph node | IHC+, FISH+ | IV | Non‐smoker | None | None | ||
| 2. Ochi et al. 2013 11 | 45 | F | Bronchial biopsy of cervical lymph node | IHC −, FISH + | IV | Smoker | None | None | ||
| 3. Alrifai et al. 2013 12 | 69 | M | Bronchial biopsy of cervical lymph node | IHC+, FISH+ | IIIa | Smoker | Radiation | None | None | |
| 4. Wang et al. 2014 13 | 55 | F | Bronchial biopsy of primary lesion | IHC+, FISH+ | IV | Non‐smoker | PDC | Crizotinib | PR | 5.8 |
| 5. Mikes et al. 2015 14 | 36 | M | Bronchial biopsy of primary lesion | IHC+, FISH+, RT‐PCR | IV | Non‐smoker | None | Crizotinib | PR | 3.0 (PR maintain |
| 6. Zhang et al. 2015 15 | 55 | F | Bronchial biopsy of primary lesion | IHC+ | IV | Non‐smoker | PDC | Crizotinib | PR | 6 |
| 7. Takanashi et al. 2015 16 | 60 | M | Bronchial biopsy of primary lesion | IHC+, FISH+, RT‐PCR+ | II | Smoker | Adjuvant | None | ||
| 8. Vergne et al. 2016 17 | 58 | F | Bronchial biopsy of primary lesion | IHC+, FISH+ | IV | Non‐smoker | None | Crizotinib | PR | 7.1 |
| 9. Tamiya et al. 2015 18 | 78 | M | Bronchial biopsy of primary lesion | IHC+, FISH+ | IV | Smoker | None | Alectinib | PD | 1.5 |
| 10. Wang et al. 2016 19 | 37 | F | Bronchial biopsy of primary lesion | IHC+ | IIIb | Non‐smoker | Radiation, PDC | Crizotinib | PR | 9 |
| 11. Yamamoto et al. 2016 20 | 76 | M | Bronchial biopsy of primary lesion | IHC−, FISH+ | IIIa | Non‐smoker | Radiation | None | ||
| 12. Mamesaya et al. 2017 21 | 52 | F | Bronchial biopsy of primary lesion | IHC+, FISH+ | IV | Non‐smoker | PDC | Alectinib | PR | 11 |
| 13. Bolzacchini et al. 2017 22 | 51 | M | Biopsy of primary lesion, surgery | IHC+, FISH+ | IIIa | Non‐smoker | PDC, | Crizotinib, Alectinib | PR | 14 |
| 14. Li et al. 2017 23 | 45 | F | Biopsy of primary lesion | IHC+, FISH+, NGS | IV | Non‐smoker | None | Crizotinib, | PR | 9 |
| 15. Sagawa et al. 2018 24 | 73 | M | Bronchial biopsy | IHC+, FISH+ | IV | Non‐smoker | None | Alectinib | PR | >9 |
| 16. Huang et al. 2018 25 | 50 | F | Lung biopsy | NGS+ | IV | Smoker | PDC | Crizotinib, Alectinib | PR/PR (QTprolong) | >4 |
| 17. Watanabe et al. 2018 26 Case 1 | 65 | F | Bronchial biopsy | IHC−; FIFH+ | IV | Smoker | PDC | Crizotinib, Alectinib | PD | 2/1 |
| Case 2 | 36 | M | Bronchial biopsy | IHC+, FISH+ | IIIb | Smoker | PDC | Crizotinib, Alectinib | PR | 12/5 |
| Case 3 | 62 | M | Bronchial biopsy | IHC−, FISH+ | IV | Smoker | PDC | Crizotinib | PD | 1 |
| 18. Wang et al. 2019 27 Case 1 | 63 | M | Bronchial biopsy | IHC+, FISH−, NGS+ | IV | Smoker | None | Crizotinib, | SD | 3 |
| Case 2 | 32 | F | Bronchial biopsy | IHC+, FISH−, NGS+ | IV | Non‐smoker | None | Crizotinib | PD | 4 |
| Case 3 | 53 | F | Bronchial biopsy surgery | IHC+, FISH+, NGS+ | IIIA | Non‐smoker | PDC | Crizotinib | SD | 9 |
| Case 4 | 73 | F | Bronchial biopsy | IHC+, FISH+, NGS+ | IV | Smoker | PDC | Crizotinib | SD | 10 |
Abbreviations: F, female; FISH, fluorescence in situ hybridization; M, male; PD, progressive disease; PDC, platinum‐doublet chemotherapy; PR, partial response; RT‐PCR, reverse transcription polymerase chain reaction; SD, stable disease.